influenza
vaccin
product
tradit
reli
use
embryon
chicken
egg
viru
isol
propag
recent
cellculturederiv
manufactur
method
introduc
influenza
vaccin
product
either
convent
cell
cultur
method
risk
incident
contamin
adventiti
agent
thu
riskassess
model
develop
qualit
assess
potenti
risk
vaccin
process
contamin
viral
pathogen
model
take
account
basic
growth
characterist
viru
abil
grow
differ
cell
substrat
resist
process
step
vaccin
manufactur
riskassess
model
appli
variou
pathogen
determin
potenti
risk
relev
differ
manufactur
scenario
use
differ
cell
substrat
viru
propag
includ
madindarbi
canin
kidney
mdck
cell
avian
virus
introduc
via
use
embryon
egg
viru
isol
found
present
greatest
risk
irrespect
substrat
use
influenza
viru
propag
use
mdck
cell
propag
vaccin
viru
eggisol
influenza
viru
strain
introduc
new
greater
adventiti
viru
risk
compar
eggbas
vaccin
product
inde
adventiti
viru
risk
potenti
reduc
fewer
virus
abl
grow
mdck
cell
annual
assess
circul
influenza
viru
strain
result
frequent
updat
composit
influenza
vaccin
essenti
afford
protect
evolv
influenza
virus
due
time
commun
composit
manufactur
influenza
vaccin
produc
accord
rigid
timescal
ensur
avail
product
onset
influenza
season
evid
contamin
observ
compress
period
vaccin
manufactur
would
critic
contamin
raw
materi
process
intermedi
influenza
vaccin
would
destroy
irrespect
form
contamin
unless
contamin
agent
could
identifi
could
convincingli
demonstr
agent
could
effect
inactiv
remov
worstcas
scenario
product
materi
would
dispos
sever
limit
influenza
vaccin
stock
upcom
influenza
season
convent
inactiv
influenza
vaccin
produc
use
embryon
chicken
egg
influenza
viru
isol
seed
viru
prepar
influenza
viru
propag
altern
influenza
vaccin
product
technolog
current
develop
includ
use
mammalian
cell
line
viru
propag
cellculturebas
manufactur
system
could
offer
product
control
allow
asept
handl
viru
product
facilit
purif
vaccin
product
influenza
viru
strain
use
vaccin
manufactur
origin
human
nasal
throat
swab
may
contamin
virus
passag
influenza
viru
embryon
egg
also
carri
risk
introduct
avian
virus
influenza
vaccin
product
timescal
permit
limit
viru
exclus
test
viru
isol
seed
viru
prepar
eg
test
avian
retrovirus
date
publish
data
presenc
adventiti
agent
influenza
vaccin
product
process
final
vaccin
product
howev
number
publish
report
presenc
retrovir
contamin
revers
transcriptas
activ
vaccin
produc
embryon
chicken
egg
primari
chicken
embryon
fibroblast
furthermor
simian
viru
exposur
subject
receiv
polio
vaccin
produc
use
polioviru
isol
monkey
kidney
cell
well
document
viral
safeti
convent
inactiv
influenza
vaccin
larg
reli
perceiv
limit
growth
human
virus
embryon
egg
viru
filter
effect
effici
viru
inactiv
purif
step
howev
littl
known
viru
filter
effect
egg
passag
furthermor
publish
data
capac
vaccin
process
place
inactiv
adventiti
agent
avail
systemat
review
often
assum
inactiv
process
complet
inactiv
like
viral
contamin
thu
viral
safeti
convent
influenza
vaccin
primarili
base
upon
histor
safeti
record
rather
specif
data
fact
novel
riskassess
model
develop
qualit
assess
risk
contamin
inactiv
split
subunit
influenza
vaccin
rang
virus
agent
cover
bacteri
steril
test
ensur
broad
applic
assess
common
element
influenza
vaccin
product
process
taken
account
addit
facilit
comparison
differ
virus
despit
limit
avail
data
relev
characterist
rate
basic
nonquantit
semiquantit
term
riskassess
model
use
simpl
score
approach
eg
high
intermedi
low
base
characterist
individu
virus
overal
process
riskscor
calcul
potenti
contamin
riskassess
model
use
identifi
potenti
contamin
risk
influenza
vaccin
manufactur
also
use
compar
rate
rel
risk
associ
virus
riskassess
model
take
account
specif
manufactur
process
also
serv
use
tool
compar
relev
potenti
contamin
differ
vaccin
manufactur
process
use
altern
cell
substrat
isol
propag
influenza
viru
risk
control
risk
reduct
measur
differ
process
develop
base
initi
assess
paper
riskassess
model
use
determin
rel
risk
rang
potenti
contamin
virus
number
influenza
vaccin
manufactur
scenario
primari
object
compar
potenti
contamin
risk
proprietari
madindarbi
canin
kidney
mdck
cellculturederiv
influenza
vaccin
optaflu
novarti
vaccin
convent
influenza
vaccin
risk
also
calcul
cell
substrat
combin
thereof
includ
vero
cell
potenti
applic
product
reassort
strain
use
revers
genet
riskassess
model
appli
virus
mycoplasma
chlamydia
speci
could
theoret
introduc
influenza
vaccin
manufactur
process
either
directli
influenza
viru
isol
design
intend
replac
processor
productspecif
assess
allow
specif
conclus
reach
safeti
particular
vaccin
product
purpos
risk
assess
provid
initi
overview
process
contamin
risk
use
prioritis
measur
taken
improv
process
robust
product
safeti
risk
assess
assign
score
specif
agent
number
paramet
base
characterist
includ
growth
properti
stabil
suscept
inactiv
discuss
detail
characterist
evalu
score
assign
characterist
summaris
tabl
describ
detail
overal
process
risk
score
calcul
specif
agent
use
defin
algorithm
fig
simpl
algorithm
base
multipl
score
assign
characterist
design
establish
whether
risk
level
maintain
reduc
increas
point
vaccin
manufactur
process
characterist
evalu
score
denot
reduc
risk
score
denot
increas
risk
score
indic
risk
level
maintain
score
given
assign
score
appropri
exampl
avian
viru
sole
cell
cultur
manufactur
scenario
form
part
subcategori
two
score
ad
rather
multipli
calcul
final
score
never
risk
assess
assign
score
base
simpl
qualit
definit
due
limit
avail
quantit
data
although
possibl
quantit
term
eg
viru
growth
titr
incorpor
accept
certain
degre
imprecis
score
deriv
risk
assess
provid
scale
differ
viru
characterist
compar
simpl
ye
paramet
two
score
given
maintain
risk
reduc
risk
greater
differenti
could
identifi
score
split
eg
viru
growth
score
high
viru
titreincreas
risk
score
maintain
viru
titremaintain
risk
score
moder
lower
viru
titredecreas
risk
shown
fig
two
score
attribut
gener
growth
properti
categori
two
score
attribut
growth
cell
substrat
categori
ad
combin
score
categori
fed
algorithm
subordin
categori
independ
low
score
one
subcategori
necessarili
result
reduct
total
risk
whole
categori
multipl
within
categori
would
inadequ
reduc
high
risk
addit
subcategori
score
maintain
higher
risk
score
add
weight
risk
confer
viral
growth
consid
appropri
sinc
viral
growth
one
relev
risk
factor
vaccin
manufactur
influenza
vaccin
manufactur
inocul
cell
substrat
influenza
strain
carri
high
dilut
avoid
growth
inhibit
defect
interf
influenza
viru
furthermor
maximum
influenza
viru
titr
usual
achiev
day
contamin
virus
grow
rapidli
effect
releas
cell
substrat
expect
yield
signific
viru
titr
therefor
score
attribut
specif
agent
base
speed
growth
maximum
score
cellfre
transmiss
maximum
score
ad
togeth
give
singl
score
gener
growth
properti
score
base
data
growth
properti
publish
literatur
studi
virus
achiev
high
titr
short
period
time
eg
peak
titr
log
tissu
cultur
infecti
dose
tcid
ml
day
assign
score
virus
either
slow
growth
low
titr
assign
score
virus
slow
growth
low
titr
eg
peak
titr
log
tcid
ml
day
assign
score
cellfre
transmiss
virus
effect
releas
cell
substrat
given
score
mainli
transmit
cell
cell
assign
score
minimum
combin
score
given
agent
recognis
score
lower
calcul
risk
differ
cell
substrat
present
differ
risk
contamin
agent
therefor
score
attribut
specif
agent
base
abil
grow
cell
substrat
use
influenza
viru
isol
propag
egg
mdck
cell
vero
cell
possibl
score
attribut
base
data
deriv
publish
literatur
standard
adher
mdck
vero
cell
cultur
serumcontain
medium
use
serumderiv
supplement
assum
scenario
cell
use
isol
earli
passag
influenza
viru
standard
mdck
cell
growth
data
entir
deriv
publish
data
vaccin
manufactur
scenario
use
mdck
suspens
cell
thu
serumfre
growth
condit
viral
growth
base
studi
result
distinguish
viral
growth
standard
mdck
cell
ie
commonli
acquir
american
type
cultur
collect
suspens
cell
cultur
inocul
contain
tcid
ml
viru
test
viru
titr
monitor
least
day
substrat
type
certain
simplif
made
viru
type
famili
exampl
parainfluenza
iii
growth
properti
taken
repres
parainfluenza
ii
iv
even
though
latter
speci
exhibit
restrict
replic
compar
parainfluenza
iii
contamin
viru
growth
unrestrict
cell
substrat
eg
peak
titr
log
tcid
ml
log
inoculum
titr
score
assign
limit
growth
contamin
viru
eg
peak
titr
log
tcid
ml
log
inoculum
titr
virus
requir
adapt
grow
cell
substrat
assign
score
viru
growth
could
confirm
growth
particular
viru
deem
unlik
score
given
inabl
particular
contamin
agent
grow
specif
cell
substrat
confirm
experiment
score
given
score
assign
specif
agent
assess
present
cell
substrat
exampl
avian
viru
sole
cell
cultur
manufactur
scenario
although
riskassess
model
processspecif
virus
score
accord
capac
surviv
purif
process
base
taxonom
characterist
environment
stabil
tabl
score
assign
stabl
virus
eg
polyomavirus
parvovirus
reovirus
assum
viru
concentr
process
might
greater
total
viru
degrad
score
assign
stabl
virus
eg
rhinovirus
enterovirus
adenovirus
greater
loss
viru
expect
exampl
unstabl
virus
score
assign
virus
vari
degre
suscept
inactiv
process
score
assign
specif
agent
base
taxonom
characterist
therefor
like
resist
inactiv
score
attribut
base
data
studi
evalu
inactiv
rang
virus
cover
taxonom
properti
use
betapropiolacton
formaldehyd
essenti
inactiv
agent
use
manufactur
vaccin
human
use
sinc
inactiv
process
inactiv
viru
certain
degre
score
attribut
tabl
virus
exhibit
resist
inactiv
agent
eg
viru
titr
reduc
log
step
commonli
appli
inactiv
process
condit
assign
score
virus
show
mark
complet
reduct
eg
log
reduct
assign
score
final
virus
inactiv
level
detect
assay
eg
reduc
log
step
score
assign
split
subunit
influenza
vaccin
undergo
deterg
treatment
step
disrupt
virion
releas
influenza
viru
surfac
membran
antigen
nonenvelop
virus
resist
treatment
assign
score
envelop
virus
suscept
deterg
disrupt
assign
score
tabl
separ
assess
perform
rate
rank
relev
viru
term
pathogen
human
score
attribut
base
degre
known
pathogen
virus
known
highli
pathogen
human
includ
human
retrovirus
sever
acut
respiratori
syndrom
coronaviru
sarscov
score
virus
known
moder
pathogen
score
virus
known
pathogen
includ
avian
anim
virus
score
virus
could
score
recognis
pathogen
factor
reduc
contamin
risk
riskassess
model
appli
variou
viru
isolationviru
propag
scenario
use
influenza
vaccin
product
isol
propag
egg
convent
influenza
vaccin
manufactur
gener
growth
properti
stabil
inactiv
split
manufactur
scenario
evalu
score
viral
growth
cell
substrat
differ
scenario
full
score
system
riskassess
calcul
virus
mycoplasma
speci
chlamydia
speci
regard
convent
eggbas
vaccin
manufactur
scenario
present
tabl
tabl
show
individu
score
assign
evalu
characterist
calcul
process
score
associ
rank
regard
pathogen
nonenvelop
avian
birnaviru
avian
polyomaviru
avian
reoviru
attribut
highest
overal
process
score
due
high
growth
potenti
egg
mammalian
reoviru
also
score
highli
rank
fourth
avian
virus
calcul
process
score
envelop
virus
includ
coronavirida
paramyxovirida
gener
low
although
herp
simplex
viru
hsv
score
quit
highli
assess
tabl
present
full
score
system
rang
virus
egg
use
influenza
viru
isol
mdck
suspens
cell
influenza
viru
propag
nonenvelop
avian
birnaviru
avian
polyomaviru
avian
reoviru
attribut
highest
overal
process
score
rang
like
mani
cell
substrat
mdck
cell
support
growth
mammalian
reoviru
demonstr
studi
mammalian
reoviru
also
score
highli
convers
studi
shown
adenovirus
polyomavirus
grow
mdck
cell
therefor
virus
associ
lower
risk
mdck
cell
use
influenza
viru
propag
compar
convent
eggbas
manufactur
process
tabl
show
calcul
overal
process
score
six
manufactur
scenario
evalu
togeth
averag
risk
score
rank
pathogen
across
differ
scenario
except
similar
process
score
obtain
pathogen
regardless
manufactur
scenario
high
score
attribut
avian
reoviru
avian
birnaviru
avian
polyomaviru
mammalian
reoviru
also
achiev
high
score
manufactur
scenario
adenovirus
jcbk
polyomavirus
achiev
higher
score
vero
cell
use
influenza
viru
propag
compar
scenario
use
vero
cell
tabl
similarli
score
human
picornavirida
increas
vero
cell
involv
mycoplasma
speci
chlamydia
speci
achiev
low
score
assess
regardless
cell
substrat
use
influenza
viru
isol
propag
tabl
also
show
sum
process
score
manufactur
scenario
give
indic
rel
risk
contamin
associ
scenario
convent
eggbas
manufactur
process
egg
egg
scenario
produc
sum
score
compar
viru
isol
egg
product
mdck
cell
egg
mdck
cell
none
individu
score
egg
mdck
scenario
higher
egg
egg
scenario
furthermor
mdck
mdck
scenario
mdck
cell
also
use
viru
isol
produc
even
lower
sum
score
higher
sum
score
obtain
vero
cell
involv
process
addit
assess
carri
take
consider
pathogen
potenti
viru
human
calcul
overal
process
score
tabl
show
final
process
score
viru
human
pathogen
score
includ
would
expect
human
virus
score
highli
mammalian
reoviru
human
adenoviru
jcbk
polyomaviru
achiev
highest
score
herp
simplex
viru
human
enteroviru
also
score
highli
despit
lack
human
pathogen
rel
high
score
attribut
avian
virus
includ
reoviru
birnaviru
polyomaviru
egg
involv
manufactur
process
inclus
pathogen
factor
process
score
affect
rank
manufactur
process
term
sum
process
score
score
lower
egg
replac
mdck
cell
inclus
vero
cell
produc
higher
sum
score
use
riskassess
model
shown
avian
virus
may
introduc
via
use
embryon
egg
repres
greatest
risk
adventiti
contamin
inactiv
subunit
influenza
vaccin
interestingli
less
wellknown
avian
virus
reoviru
birnaviru
polyomaviru
greatest
threat
wherea
avian
retrovirus
appear
less
relev
would
expect
avian
virus
gener
score
high
egg
use
influenza
viru
propag
well
influenza
viru
isol
although
avian
virus
apathogen
human
may
less
relev
final
influenza
vaccin
human
pathogen
kind
contamin
influenza
vaccin
manufactur
could
disrupt
vaccin
product
hinder
time
distribut
influenza
vaccin
would
expect
embryon
egg
replac
mdck
cell
cultur
isol
influenza
strain
risk
avian
viru
enter
vaccin
manufactur
process
elimin
human
virus
analys
wellknown
pathogen
achiev
low
score
mammalian
reoviru
prove
carri
highest
risk
assess
reovirus
common
speci
tend
grow
almost
cell
type
studi
shown
reovirus
resist
chemic
inactiv
like
surviv
downstream
purif
step
due
stabl
doublestrand
nucleic
acid
materi
capsid
structur
compar
nonenvelop
virus
adenovirus
polyomavirus
enterovirus
also
link
rather
higher
risk
pathogen
particularli
vero
cell
use
stage
envelop
virus
gener
suscept
chemic
inactiv
method
deterg
treatment
use
downstream
process
influenza
vaccin
manufactur
envelop
virus
achiev
low
score
except
hsv
studi
publish
literatur
found
hsv
grow
rapidli
cell
substrat
evalu
assess
use
riskassess
model
shown
use
mdck
cell
influenza
viru
propag
eggderiv
influenza
isol
egg
mdck
potenti
reduc
chanc
viral
contamin
compar
convent
eggbas
influenza
vaccin
manufactur
egg
egg
fewer
virus
abl
grow
mdck
cell
substrat
use
mdck
cell
viru
propag
increas
rel
risk
pose
human
pathogen
compar
convent
eggbas
vaccin
manufactur
manufactur
process
involv
isol
product
influenza
viru
mdck
cell
associ
lowest
risk
viral
contamin
threat
avian
contamin
egg
remov
therefor
qualit
assess
support
suitabl
mdck
cell
influenza
viru
isol
product
import
find
mdck
cell
use
influenza
viru
isol
isol
yet
use
vaccin
manufactur
due
unknown
risk
contamin
extran
virus
current
eggderiv
isol
use
influenza
vaccin
manufactur
furthermor
use
mdck
cell
influenza
viru
isol
product
may
provid
vaccin
closer
antigen
match
influenza
strain
circul
human
popul
vaccin
viru
strain
isol
egg
closer
antigen
match
may
result
improv
immunogen
respons
vaccin
recipi
riskassess
model
appli
manufactur
scenario
use
vero
cell
increas
maintain
overal
risk
compar
scenario
vero
cell
support
growth
wide
rang
virus
includ
mani
human
pathogen
vero
cell
use
instead
egg
influenza
viru
isol
propag
contamin
avian
virus
avoid
howev
risk
contamin
virus
either
maintain
increas
eg
adenovirus
polyomavirus
enterovirus
rhinovirus
reoviru
varicella
zoster
viru
combin
egg
influenza
viru
isol
vero
cell
passag
introduc
even
higher
risk
possibl
contamin
avian
virus
latter
scenario
would
like
appli
futur
applic
vero
cellbas
reversegenet
techniqu
produc
influenza
strain
plasmidbas
techniqu
includ
measur
reduc
initi
contamin
viru
strain
exclud
contamin
origin
human
oper
cell
cultur
incorpor
human
pathogen
factor
risk
assess
alter
rank
virus
term
overal
process
score
mammalian
reoviru
human
adenoviru
jcbk
polyomaviru
human
enteroviru
continu
score
highli
sever
avian
virus
includ
avian
reoviru
birnaviru
polyomaviru
result
describ
appli
inactiv
split
subunit
influenza
vaccin
omit
virussplit
score
step
model
could
easili
appli
manufactur
wholeviru
vaccin
consider
pandem
influenza
vaccin
assess
live
attenu
influenza
vaccin
score
gener
growth
properti
growth
cell
substrat
stabil
would
appli
specif
applic
riskassess
model
also
modifi
includ
viru
exclus
test
exampl
polymeras
chain
reaction
convent
test
cell
cultur
vivo
score
follow
test
avail
abl
detect
exist
strain
suitabl
test
avail
would
expect
addit
step
would
produc
major
effect
score
virus
grow
well
cell
substrat
use
viru
propag
riskassess
model
present
provid
initi
overview
adventiti
viru
risk
manufactur
influenza
vaccin
risk
assess
processspecif
model
offer
consider
flexibl
rang
applic
consid
use
tool
evalu
virusspecif
contamin
risk
vaccin
manufactur
import
note
assess
describ
use
evalu
viral
safeti
specif
vaccin
term
risk
vaccin
recipi
instead
processspecif
evalu
must
carri
exampl
describ
separ
paper
specif
data
relat
process
contamin
event
rare
publish
model
describ
valid
materi
data
instead
paper
consid
attempt
open
discuss
risk
model
evalu
use
data
becom
avail
particular
detail
inform
presenc
frequenc
contamin
virus
embryon
egg
earli
influenza
viru
isol
obtain
differ
cell
substrat
would
valuabl
viral
safeti
assess
normal
carri
determin
consequ
human
pathogen
contamin
final
vaccin
product
howev
primari
focu
risk
assess
probabl
contamin
event
viru
irrespect
pathogen
potenti
human
particularli
relev
influenza
vaccin
manufactur
discoveri
sort
viral
contamin
would
critic
technic
counter
measur
drawn
risk
assess
appli
lowand
highpathogen
virus
influenza
vaccin
manufactur
worldwid
suppli
refer
viru
isol
influenza
vaccin
produc
accord
rigid
timescal
evid
nonpathogen
contamin
like
neg
impact
vaccin
manufactur
would
present
commerci
risk
vaccin
manufactur
may
also
present
public
health
risk
due
delay
vaccin
suppli
